Abstract
Anaphylaxis, a potentially fatal allergic reaction with an increasing incidence and severity continues to be underdiagnosed and undertreated.1 Intramuscular (IM) epinephrine is the first-line treatment in any age group,1 and delay in administration is associated with a higher risk of fatality.2 Rates of epinephrine under treatment in the outpatient setting and in the emergency department (ED) range between 25% and 60%,3-6 even following intervention programs.6 Predictors for epinephrine undertreatment have been poorly studied.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
